Zeng R, Pu H, Zhang X, Yao M, Sun Q
Chin J Integr Med. 2023; 29(7):665-672.
PMID: 37074617
DOI: 10.1007/s11655-023-3635-y.
Deng B, Tang X, Wang Y
Front Endocrinol (Lausanne). 2022; 13:999211.
PMID: 36204112
PMC: 9530452.
DOI: 10.3389/fendo.2022.999211.
Yang X, Zhao H, Liu X, Xie Q, Zhou X, Deng Q
Front Psychiatry. 2020; 11:594766.
PMID: 33362607
PMC: 7759545.
DOI: 10.3389/fpsyt.2020.594766.
Badisa R, Wiley C, Randell K, Darling-Reed S, Latinwo L, Agharahimi M
Sci Rep. 2019; 9(1):9412.
PMID: 31253835
PMC: 6599005.
DOI: 10.1038/s41598-019-45845-1.
Yang X, Wang Y, Li Q, Zhong Y, Chen L, Du Y
Front Mol Neurosci. 2018; 11:186.
PMID: 29915529
PMC: 5994595.
DOI: 10.3389/fnmol.2018.00186.
The relationship between impulsivity and methamphetamine use severity in a community sample.
Moallem N, Courtney K, Ray L
Drug Alcohol Depend. 2018; 187:1-7.
PMID: 29626740
PMC: 6410745.
DOI: 10.1016/j.drugalcdep.2018.01.034.
The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.
Sambo D, Lebowitz J, Khoshbouei H
Pharmacol Ther. 2018; 186:152-167.
PMID: 29360540
PMC: 5962385.
DOI: 10.1016/j.pharmthera.2018.01.009.
Identification of Novel Signal Transduction, Immune Function, and Oxidative Stress Genes and Pathways by Topiramate for Treatment of Methamphetamine Dependence Based on Secondary Outcomes.
Niu T, Li J, Wang J, Ma J, Li M
Front Psychiatry. 2018; 8:271.
PMID: 29321746
PMC: 5733474.
DOI: 10.3389/fpsyt.2017.00271.
Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.
Runarsdottir V, Hansdottir I, Tyrfingsson T, Einarsson M, Dugosh K, Royer-Malvestuto C
J Addict Med. 2017; 11(3):197-204.
PMID: 28379861
PMC: 5449233.
DOI: 10.1097/ADM.0000000000000297.
RasGRP1 promotes amphetamine-induced motor behavior through a Rhes interaction network ("Rhesactome") in the striatum.
Shahani N, Swarnkar S, Giovinazzo V, Morgenweck J, Bohn L, Scharager-Tapia C
Sci Signal. 2016; 9(454):ra111.
PMID: 27902448
PMC: 5142824.
DOI: 10.1126/scisignal.aaf6670.
The Anorexigenic Peptide Neuromedin U (NMU) Attenuates Amphetamine-Induced Locomotor Stimulation, Accumbal Dopamine Release and Expression of Conditioned Place Preference in Mice.
Vallof D, Vestlund J, Engel J, Jerlhag E
PLoS One. 2016; 11(5):e0154477.
PMID: 27139195
PMC: 4854378.
DOI: 10.1371/journal.pone.0154477.
Effects of DDIT4 in Methamphetamine-Induced Autophagy and Apoptosis in Dopaminergic Neurons.
Li B, Chen R, Chen L, Qiu P, Ai X, Huang E
Mol Neurobiol. 2016; 54(3):1642-1660.
PMID: 26873849
DOI: 10.1007/s12035-015-9637-9.
A Pilot Study for Discovering Candidate Genes of Chromosome 18q21 in Methamphetamine Abusers: Case-control Association Study.
Lee B, Park J, Lee Y, Moon E, Jeong H, Chung Y
Clin Psychopharmacol Neurosci. 2014; 12(1):54-64.
PMID: 24851122
PMC: 4022767.
DOI: 10.9758/cpn.2014.12.1.54.
The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.
Egecioglu E, Engel J, Jerlhag E
PLoS One. 2013; 8(7):e69010.
PMID: 23874851
PMC: 3712951.
DOI: 10.1371/journal.pone.0069010.
Steve Sussman on Matilda Hellman's "Mind the gap! Failure in understanding key dimensions of an addicted drug user's life" addictive effects.
Sussman S
Subst Use Misuse. 2012; 47(13-14):1661-5.
PMID: 23186503
PMC: 4181842.
DOI: 10.3109/10826084.2012.723898.
An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans.
Dean A, Groman S, Morales A, London E
Neuropsychopharmacology. 2012; 38(2):259-74.
PMID: 22948978
PMC: 3527116.
DOI: 10.1038/npp.2012.179.
Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.
McFadden L, Hunt M, Vieira-Brock P, Muehle J, Nielsen S, Allen S
Drug Alcohol Depend. 2012; 126(1-2):87-94.
PMID: 22647900
PMC: 3546538.
DOI: 10.1016/j.drugalcdep.2012.04.020.
Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
Owens S, Atchley W, Hambuchen M, Peterson E, Gentry W
CNS Neurol Disord Drug Targets. 2012; 10(8):892-8.
PMID: 22229314
PMC: 3653579.
DOI: 10.2174/187152711799219370.
Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine in rats.
White S, Laurenzana E, Hendrickson H, Gentry W, Owens S
Drug Metab Dispos. 2011; 39(9):1718-26.
PMID: 21632964
PMC: 3164273.
DOI: 10.1124/dmd.111.039446.
Methamphetamine users show greater than normal age-related cortical gray matter loss.
Nakama H, Chang L, Fein G, Shimotsu R, Jiang C, Ernst T
Addiction. 2011; 106(8):1474-83.
PMID: 21438934
PMC: 3135731.
DOI: 10.1111/j.1360-0443.2011.03433.x.